24916-90-3

• 常用中文名：地塞米松环氧水解物
• 常用英文名：Dexamethasone 9,11-epoxide
• CAS号：24916-90-3
• 分子式：C₂₂H₂₈O₅
• 分子量：372.455
• 相关类别： 研究领域 炎症/免疫
• 发布时间：2018-09-27 19:11:41
• 更新时间：2026-08-02 19:49:08
• Dexamethasone 9,11-epoxide是来自专利CN 106520896 A和RU 2532902 C1的化合物,是制备地塞米松的中间体。

名称

• 中文名: 地塞米松环氧水解物
• 英文名: Dexamethasone 9,11-Epoxide
• 中文别名: 地塞米松杂质4(地塞米松杂质D); 地塞米松杂质D(糠酸莫米松杂质L); 地塞米松杂质D(MOMETASONE FURATE 杂质L,去氧肟酮松杂质D); 地塞米松 9,11-环氧基; 糠酸莫米松杂质L; 化合物:Dexamethasone 9,11-oxide; 倍他米松环氧物; 地塞米松磷酸钠杂质D; 地塞米松杂质D(地塞米松杂质D,莫米松糠酸酯杂质L); 8DM醋酸酯/地塞米松环氧水解物; 地塞米松环氧水解物(8-DM); 地塞米松环氧水解物,10 MM DMSO 溶液; 糠酸莫米松杂质12(糠酸莫米松杂质L); 地塞米松环氧水解物/地塞米松9,11-环氧; 糠酸莫米松杂质L(地塞米松杂质D); 地塞米松杂质D; 8DM,地塞米松环氧水解物; 倍他米松环氧物 8DM; 莫美他松杂质D; 甲羟环氧孕酮(8-DM); DIVBIO/深创生物，Dexamethasone9,11-oxide，倍他米松环氧水解物; 地塞米松 9,11-环氧化物; 糠酸莫米松杂质43; 莫米松杂质L; 去氧米松杂质D; 化合物：Dexamethasone 9,11-oxide; DIVBIO/深创生物,Dexamethasone9,11-oxide,倍他米松环氧水解物; 倍他米松环氧水解物; 去氧西米松杂质D(地塞米松杂质D,糠酸莫米松杂质L); 地塞米松杂质杂质D; 地塞米松9,11-环氧; 9Β,11Β-环氧-16Β-甲基孕甾-1,4-二烯-17Α,21-二醇-3,20-二酮; 地塞米松环氧水解物倍他米松环氧物; (4AS,4BS,5AS,6AS,7R,8R,9AS,9BS)-7-羟基-7-(2-羟基乙酰基)-4A,6A,8-三甲基-A,6,6A,7,8,9,9A,9B,10,11-十氢环戊二烯并[1,2]菲并[4,4A-B]环氧乙烯-2(4AH)-酮; 地塞米松环氧水解物/地塞米松杂质D
• 英文别名: (9b,11b,16a)-9,11-oxy-17,21; 9SS,11SS-OXY-17,21-DIHYDROXY-16A-METHYLPREGNA-1,4-DIENE-3,20-DIONE; 9,11BETA-OXY-17,21-DIHYDROXY-16ALPHA-METHYL-9BETA-PREGNA-1,4-DIENE-3,20-DIONE; Dexamethasone Impurity D; Pregna-1,4-diene-3,20-dione,9,11-oxy-17,21-dihydroxy-16-Methyl-, (9b,11b,16a); 16ALPHA-METHYL OXIDE(8DM); dexamethasone 8; 16-beta Methyl oxi; 3TR(TETRAENEACETATE); Desoximetasone Impurity D (Dexamethasone Impurity D, Mometasone Furoate Impurity L); DOB-MN; 16-β Methyl Epoxide; 16-Methyloxide; 9,11B-OXY-17,21-DIHYDROXY-16A-METHYL-9B-PREGNA-1,4-DIENE-3,20-DIONE; 8-Dm24-3; 16 beta-methyl oxy; Mometasone Furoate Impurity 12（Mometasone Furoate Impurity L）; (9B,11B,16A)-9,11-OXY-17,21-DIHYDROXY-16-METHYL-PREGNA-1,4-DIENE-3,20-DIONE 24-3; Mometasone Impurity L; Dexamethasone Impurity D (Mometasone Furoate Impurity L); betamethasone 11; 5-(2,3-dichlorophenyl)azo-4,6-dimethyl-2-pyrimidinamine; (9β,11β,16α)-17,21-Dihydroxy-16-methyl-9,11-epoxypregna-1,4-diene-3,20-dione; Desoximetasone Impurity D; 8DM(16a-Methyl-oxide; Dexamethasone Impurity D (Mometasone Furoate Impurity L, Desoximetasone Impurity D); 16Beta-methyl oxide[8DM]; 9beta,11beta-oxy-17,21-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9β,11β-oxy-17,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione; (9β)-9,11β-oxy-17,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione; 8DM; 16 α-Methyl oxide(8-DM); 17-Hydroxy-9,11-oxy-16-methylpregna-1,4-diene-3,20-dione; (4aS,4bS,5aS,6aS,7R,8R,9aS,9bS)-7-hydroxy-7-(2-hydroxyacetyl)-4a,6a,8-triMethyl-5a,6,6a,7,8,9,9a,9b,10,11-decahydrocyclopenta[1,2]phenanthro[4,4a-b]oxiren-2(4aH)-one; MFCD07782140; 9BETA,11BETA-OXY-17,21-DIHYDROXY-16ALPHA-METHYLPREGNA-1,4-DIENE-3,20-DIONE; 9beta,11beta-oxy-17,21-dihydroxy; 8-DM , 9BETA,11BETA-OXY-17,21-DIHYDROXY-16ALPHA-METHYLPREGNA-1,4-DIENE-3,20-DIONE; (9,11,16a)-9,11-oxy-17,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 9,11-oxy-17,21-dihydroxy-16-methyl-, (9β,11β,16α); Mometasone Furoate Impurity L (Dexamethasone Impurity D); 9,11-oxy-17,21-dihydroxy-16-methyl-(9-beta-11-beta-16-alpha)-Pregna-1,4-diene-3,20-dione; 17α,21-Dihydroxy-16α-methyl-9β,11β-oxypregna-1,4-diene-3,20-dione; 9,11B-OXY-17,21-DIHYDROXY-16B-METHYL-9B-PREGNA-1,4-DIENE-3,20-DIONE; 9β,11β-oxy-17,21-dihydroxy-16α-methylpregna-1,4-diene-3; (4aS,4bS,5aS,6aS,7R,8R,9aS,9bS); Clorcortolone interMediate 1- Pregna-1,4-diene-3,20-dione, 9,11-oxy-17,21-dihydroxy-16-Methyl-, (9β,11β,16α); 9,11-oxy-16-methylpregna-1,4-diene-17,21-diol-3,20-dione; EINECS 213-563-4; Dexamethasone 9,11-oxide; 16-ALPHA METHYL OXIDE; 16 beta-methyl oxy 21-acetate; 8DM (16α-Methyl-oxide); Dexamethasone-9(11)-β-oxide; 16 Beta-Methyl oxide 21-Acetate; (9b,11b,16a)-9,11-oxy-17,21-dihydroxy-16-methyl-pregna-1,4-diene-3,20-dione; Dexamethasone Impurity 4(Dexamethasone Impurity D); 16beta-Methyl; 16-A METHYL EOPOXIDE; (4aS,4bS,5aS,6aS,7R,8R,9aS,9bS)-7-Glycoloyl-7-hydroxy-4a,6a,8-trimethyl-5a,6,6a,7,8,9,9a,9b,10,11-decahydrocyclopenta[7,8]phenanthro[4b,5-b]oxiren-2(4aH)-one; (9β,11β,16β)-17,21-Dihydroxy-16-methyl-9,11-epoxypregna-1,4-diene-3,20-dione

物化性质

• 密度: 1.3±0.1 g/cm3
• 沸点: 564.9±50.0 °C at 760 mmHg
• 熔点: 210-220ºC
• 分子式: C₂₂H₂₈O₅
• 分子量: 372.455
• 闪点: 198.1±23.6 °C
• 精确质量: 372.193665
• PSA: 87.13000
• LogP: 2.23
• 外观性状: 灰白-黄色固体
• 蒸汽压: 0.0±3.5 mmHg at 25°C
• 折射率: 1.616
• 储存条件: Refrigerator

生物活性

• 描述: Dexamethasone 9,11-epoxide是来自专利CN 106520896 A和RU 2532902 C1的化合物,是制备地塞米松的中间体。
• 相关类别:
  信号通路 >> 其他 >> 其他
  研究领域 >> 炎症/免疫
• 参考文献:

  [1]. CN 106520896 A

  [2]. RU 2532902 C1

安全

• 海关编码: 2937290090

上下游产品

上游产品  2
78761-59-8 89561-92-2
下游产品  3
2884-51-7 83919-23-7 105102-22-5

制备

【方法一】
可用海可吉宁经乙酰化、消除（脱氢）、还原、开环、环氧化、乙酰化、缩酮化、加成、溴化、置换、氧化、消除、加成、环合等步反应制得该品。

海关

海关编码	2937290090